Monthly Archives: August 2008

US FDA clears non-invasive test to help doctors manage heart transplant patients

August 29th, 2008|

The US Food and Drug Administration has cleared for marketing a non-invasive test that uses molecular expression techniques to assist doctors in managing heart transplant patients post-surgery for potential organ rejection.

Truman Medical Centers Installs Adaptive 128-slice CT Scanner

August 29th, 2008|

Truman Medical Centers (TMC) became one of the first hospitals in the United States to install the Siemens SOMATOM Definition AS 128 slice CT scanner this week. The 128-slice CT scanner is a highly adaptive scanner, providing exceptional image quality with minimal radiation exposure to the patient.

Peakdale Molecular Launches AssayReady4U(TM)

August 29th, 2008|

Peakdale Molecular has launched AssayReady4U(TM) an online based storefront which allows drug discovery researchers the ability to search, design and select compounds from a live physical collection of screening compounds in collaboration with ChemPrintCo LLC .

Novartis takes $235 million charge after stopping trial

August 29th, 2008|

Novartis AG stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials, and said it would take a $235 million impairment charge.

Dr Reddy’s gets FDA nod for trandolapril tabs

August 29th, 2008|

Dr Reddy's Laboratories Ltd has received approval from the U.S. Food and Drug Administration for trandolapril tablets, the regulator's website showed.

CMS, Inc treats First Cancer Patients Treated With Monaco(TM) Radiation

August 29th, 2008|

CMS, Inc., an Elekta Company and worldwide leader in radiation treatment planning and workflow management solutions, announced that three sites have delivered clinical treatments utilizing Monaco(TM), its next-generation Intensity Modulated Radiotherapy (IMRT) treatment planning system.

Teva’s Phase III Parkinson’s disease trial meets endpoint

August 28th, 2008|

Israel-based Teva Pharmaceutical Industries has announced positive results of its Phase III Adagio trial.

Vitrolife: Approval for STEEN Solution(TM) Study

August 28th, 2008|

Vitrolife has received approval from the Canadian authorities to start a study with STEEN Solution(TM). The study, which has been designed in consultation with the American FDA, is planned for quarters three to four of 2008 and will be the key element in the application for sales approval in USA and Canada.

New Treatment Launched to Help Improve Symptoms in People Suffering From Overactive Bladder

August 28th, 2008|

Pfizer Limited has launched Toviaz®(Black Triangle Drug) (fesoterodine fumarate), a new once daily treatment for the symptoms of overactive bladder (OAB).

New nanotechnology center helps turn big ideas into real products

August 28th, 2008|

Edmonton's Research Park in Canada – new center, the first of its kind in Canada – will give entrepreneurs a place to turn ideas into viable, market-ready products.

Marksans Pharma acquires UK based RelonChem

August 28th, 2008|

Marksans Pharma, a Rs 240-crore plus Mumbai-based pharmaceutical company, has acquired RelonChem Ltd, one of UK's leading generic drug company for an undisclosed sum. RelonChem has clocked sales of US$ 32 million with adjusted EBITDA of US $5 million in 2007.

DSM Anti-Infectives receives European COS for Purimox

August 28th, 2008|

Purimox (Amoxicillin Trihydrate) manufactured by DSM Anti-Infectives (DAI) at its Toansa India plant has received European Certificate of Suitability. 

Cordis’s Cypher Select stent wins CE mark approval

August 28th, 2008|

Cordis has received CE mark approval to market the Cypher Select plus Sirolimus-eluting coronary stent for the treatment of acute myocardial infarction, more commonly known as a heart attack.

Cervical cancer advances give hope to poor

August 28th, 2008|

New screening tests and effective vaccines from Merck & Co and GlaxoSmithKline make tackling cervical cancer in poor countries a real possibility for the first time, researchers.

Cell Genesys Halts VITAL-2 GVAX Trial in Advanced Prostate Cancer

August 28th, 2008|

Cell Genesys, Inc. today announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere® (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer.

Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program

August 28th, 2008|

Bristol-Myers Squibb Company and Pfizer Inc provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).

Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin

August 28th, 2008|

Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The results support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC).

Sun Pharma wins case against Taro

August 27th, 2008|

Sun Pharmaceutical Industries Ltd. (Sun Pharma) said following the favourable Tel-Aviv court ruling in a case against Taro Pharmaceutical Industries Ltd. (Taro), it will be able to complete a previously announced tender offer to buy the outstanding shares in Taro.

Gleevec Receives US FDA Priority Review for kit-positive GIST

August 27th, 2008|

Novartis announced today that Gleevec® (imatinib mesylate) tablets* has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

US FDA Clears Stereotaxis Magnetic Radio Frequency Guidewire

August 27th, 2008|

Stereotaxis, Inc. announced today that it has received regulatory clearance from the U.S. Food and Drug Administration for its magnetically tipped, PowerAssert(TM) radiofrequency (RF) guidewire to cross chronic total occlusions in the peripheral vasculature.